You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Reversal of Tau Pathology with MSUT2 siRNA Conjugates

    SBC: DTx Pharma, Inc.            Topic: NIA

    Project Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis

    SBC: XFIBRA, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community

    SBC: EPERTURE LLC            Topic: NIA

    Project Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction

    SBC: MOLECULAR EXPRESS, INC            Topic: R42

    DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. HBI-002 to Prevent Anthracycline-Related Cardiotoxicity

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NHLBI

    PROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Gene and Oligonucleotide Delivery System

    SBC: MOLECULAR EXPRESS, INC            Topic: NCATS

    DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas

    SBC: NEONC TECHNOLOGIES INC            Topic: 102

    Despite important advances in surgical techniques, imagistic modalities and computer-assisted stereotactic delivery of radiation therapy, the prognosis for patients with glioblastoma (GB) remains grim and has not significantly changed in decades. The Stupp protocol—i.e., concurrent temozolomide (TMZ) plus conformal external beam radiotherapy (EBRT) followed by adjuvant TMZ—remains the cornerst ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD

    SBC: SAMAY, INC.            Topic: NHLBI

    ABSTRACTChronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospitalization in the US. Exacerbations - a worsening or “flare up” of symptoms - cause most COPD hospitalizations. Since most exacerbations can be treated with changes of inhalers and/or oral medications, at-home detection of lung function deterioration may facilitate earlier intervention and help delay or pre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Efficacy of a novel small-molecule splicing modulator in chronic lymphocytic leukemia (CLL)

    SBC: Wildflower Biopharma Inc            Topic: 102

    Project Summary/Abstract Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in Western countries. Despite recent treatment advances, CLL remains incurable. In the era of emerging targeted therapies, disease progression and relapse increasingly are key challenges faced by CLL patients. Therefore, there is an ongoing need for the identification of targetable vulnerabilities in t ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A novel role for Reelin therapeutics in inflammatory bowel disease

    SBC: REELIN THERAPEUTICS, INC.            Topic: 300

    Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government